Drug Type Small molecule drug |
Synonyms PF 4191834, PF-4191834 |
Target |
Mechanism 5-LOX inhibitors(Arachidonate 5-lipoxygenase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23N3O2S |
InChIKeyDVNQWYLVSNPCJZ-UHFFFAOYSA-N |
CAS Registry1029317-21-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | US | 01 Jul 2010 | |
Osteoarthritis, Knee | Phase 2 | CA | 01 Jul 2010 | |
Osteoarthritis, Knee | Phase 2 | SE | 01 Jul 2010 | |
Pain | Phase 2 | US | 01 Jul 2010 | |
Pain | Phase 2 | CA | 01 Jul 2010 | |
Pain | Phase 2 | SE | 01 Jul 2010 | |
Asthma | Phase 2 | US | 01 Jul 2008 |
Phase 2 | 190 | Naproxen placebo+PF-04191834 (PF-04191834 Followed by Placebo) | qcvvmontwc(ojjdluqtae) = urzqsnqnxq lerpftlvdn (kdnvvqgtxs, ohwwsuaoed - lsqwdoawlx) View more | - | 21 May 2013 | ||
Naproxen placebo+PF-04191834 (Placebo Followed by PF-04191834) | qcvvmontwc(ojjdluqtae) = wgdnfxwtit lerpftlvdn (kdnvvqgtxs, zjwkryonvf - pcytzdghyq) View more | ||||||
Phase 2 | 15 | Placebo | uamckcoikb(oynxorxtsd) = shlxbauzap jdbrojuzas (ubsciaigqa, sftftcdetg - uocghwiadt) View more | - | 01 Feb 2013 |